SCHEMBL1860830

SCHEMBL1860830

O=C(O)N(CCCCC1CCC(F)CC1)NCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.41
HDAC3 O15379 4/20 0.39
HDAC1 Q13547 4/20 0.39
HDAC2 Q92769 4/20 0.39
HDAC8 Q9BY41 4/20 0.39
HDAC4 P56524 2/20 0.39
HDAC7 Q8WUI4 2/20 0.39
HDAC10 Q969S8 2/20 0.39
HDAC11 Q96DB2 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
HDAC9 Q9UKV0 2/20 0.39
HDAC5 Q9UQL6 2/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ACHE P22303 2/20 0.37
NCOR2 Q9Y618 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1861192 0.90 SIGMAR1 (0.52) SIGMAR1HDAC3HDAC1HDAC2HDAC8
SCHEMBL8939728 0.70 SLC18A3 (0.50) MEN1KMT2A
SCHEMBL3085177 0.70 NPC1 (0.48) HDAC3HDAC1HDAC2HDAC8MEN1
SCHEMBL9286682 0.69 ADH1B (0.40) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL28034055 0.67 LMNA (0.49) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL1861268 0.67 SIGMAR1 (0.46) SIGMAR1HDAC3HDAC1HDAC2HDAC8
SCHEMBL5166106 0.63 MEN1 (0.53) HDAC3HDAC1HDAC2HDAC8MEN1
SCHEMBL22482261 0.63 KDM4E (0.46) HDAC3HDAC1HDAC2HDAC8MEN1
SCHEMBL7074490 0.63 NPC1 (0.44) HDAC3HDAC1HDAC2HDAC8MEN1
SCHEMBL25978993 0.63 GBA1 (0.59)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors DNPEP, PEPD, ACE SIGMAR1 4510/4885HDAC3 3096/4885HDAC1 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.